Corticosteroid treatment in severe patients with SARS-CoV-2 and chronic HBV co-infection: a retrospective multicenter study

Table 4 The comparison of primary and secondary outcomes of patients with severe COVID-19 and HBV co-infection according to corticosteroids and non-corticosteroids treatment after IPTW analysis (on admission)

Outcome	OR	95% CI	P value
Primary outcomes
28-day mortality	4.901	1.682–14.283	0.004
In-hospital mortality	5.637	1.949–16.299	0.001
Secondary outcomes
Acute liver injury	4.495	2.574–7.852	< 0.001
Acute kidney injury	1.031	0.466–2.278	0.940
Acute cardiac injury	1.163	0.554–2.439	0.690
Invasive mechanical ventilation	0.481	0.226–1.023	0.057
CRRT	0.230	0.032–1.653	0.144
SARS-CoV-2 RNA positive more than 20 days	2.945	1.631–5.317	< 0.001
Sepsis shock	0.384	0.202–0.730	0.004
ARDS			> 0.999

COVID-19: coronavirus disease 2019; HBV: hepatitis B virus; CRRT: continuous renal replacement therapy; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; ARDS: acute respiratory distress syndrome; OR: odds ratio; CI: confidence intervals
P values indicate differences between corticosteroid and non-corticosteroid. P < 0.05 was considered statistically significant

ISSN: 1471-2334